TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation

Summary

This is a single center randomized double blind controlled study of patients (BMI ≥ 27 kg/m2) with obesity and Atrial Fibrillation (AFIB) randomized to Tirzepatide vs. placebo. It is expected that the significant weight loss with Tirzepatide will result in improved control, management, symptom severity, and burden of AFIB at 12 months.

Timeline

Start

2025-04-08

Primary completion

2026-12-31

Completion

2027-06-01

Drugs

Indications